Two propensity score-based strategies for a three-decade observational study: Investigating psychotropic medications and suicide risk

Statistics in Medicine

Volumn 31, Issue 27, 2012, Pages 3255-3260

  Leon, Andrew C ^a   Demirtas, Hakan ^b   Li, Chunshan ^a   Hedeker, Donald ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antidepressant; Antiepileptic; Propensity score; Suicide

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; PSYCHOTROPIC AGENT;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG USE; HEALTH STATISTICS; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; MOOD DISORDER; OBSERVATIONAL STUDY; PROPENSITY SCORE; RISK ASSESSMENT; SAMPLE SIZE; STRATIFIED SAMPLE; SUICIDE; SUICIDE ATTEMPT; SURVIVAL;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; DATA INTERPRETATION, STATISTICAL; DEPRESSIVE DISORDER, MAJOR; HUMANS; LONGITUDINAL STUDIES; MODELS, STATISTICAL; PROSPECTIVE STUDIES; RISK; SUICIDE; UNITED STATES;

EID: 84869079202     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5339     Document Type: Article

References (24)

1. United States Food and Drug Administration. Antidepressant use in children, adolescents, and young adults. 2007 Revisions to product labeling. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf (Accessed September 18, 2011).
2. United States Food and Drug Administration. Antiepileptic drugs and suicidality, 2009. http://www.fda.gov/CDER/Drug/infopage/antiepileptics/default.htm (Accessed September 18, 2011).
3. United States Food and Drug Administration. Briefing document for Psychopharmacologic Drugs Advisory Committee, December 13, 2006. page 38. www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf (Accessed September 2, 2010).
4. Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet-Neurolology 2007; 6:693-698.
5. Nilsson L, Ahlbom A, Farahmand BY, Asberg M, Tomson T. Risk factors in suicide in epilepsy: a case-control study. Epilepsia 2002; 43:644-651.
6. Ratcliffe GE, Enns MW, Belik SL, Sareen J. Chronic pain conditions and suicidal ideation and suicide attempts: an epidemiologic perspective. Clinical Journal of Pain 2008; 24:204-210.
7. Tsai SY, Kuo CJ, Chen CC, Lee HC. Risk factors for completed suicide in bipolar disorder. Journal of Clinical Psychiatry 2002; 63:469-476.
8. Simon GE, Hunkeler E, Fireman B, Lee JY, Savarino J. Risk of suicide attempt and suicide death in patients treated for bipolar disorder. Bipolar Disorders 2007; 9:526-30.
9. United States Food and Drug Administration. Antiepileptic drugs and suicidality: Statistical review and evaluation. 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf Accessed April 19, 2011.
10. Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? Journal of Clinical Psychiatry 2003; 64:1091-1093.
11. Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J, Keller MB. Antidepressants and Risks of Suicide and Suicide Attempts: A 27-Year Observational Study. Journal of Clinical Psychiatry 2011; 72:580-586.
12. Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J, Keller MB. Antiepileptic Drugs for Bipolar Disorder and the Risk of Suicidal Behavior: A 30 Year Observational Study. American Journal of Psychiatry 2012; 169(3):285-291.
13. Katz MM, Klerman GL. Introduction: Overview of the clinical studies program of the NIMH clinical research branch collaborative study on psychobiology of depression. American Journal of Psychiatry 1979; 136:49-51.
14. Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
15. Leon AC, Hedeker D, Teres JJ. Bias Reduction in Effectiveness Analyses of Longitudinal Ordinal Doses with a Mixed-Effects Propensity Adjustment. Statistics in Medicine 2007; 26:110-123.
16. Hedeker D, Siddiqui O, Hu FB. Random-effects regression analysis of correlated grouped-time survival data. Statistical Methods in Medical Research 2000; 9:161-179.
17. Hedeker D, Gibbons RD, Du Toit SHC, Patterson D. SuperMix - A program for mixed-effects regression models. Scientific Software International: Chicago, 2008.
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959; 22:719-748.
19. Gu X, Rosenbaum PR. Comparison of Multivariate Matching Methods: Structures, Distances, and Algorithms. Journal of Computational and Graphical Statistics 1993; 2:405-420.
20. Hansen BB. Full matching in an observational study of coaching for the SAT. Journal of the American Statistical Association 2004; 99:609-618.
21. Hansen BB, Klopfer SO. Optimal full matching and related designs via network flows. Tech. Rep. 416, Statistics Department, University of Michigan, 2005.
22. Kleyman Y, Hansen B. Basic uses of the optmatch package. R documentation, 2005. http://www.stat.lsa.umich.edu/bbh/optmatch/doc/optmatch.pdf.
23. Drake C. Effects of misspecification of the propensity score on estimators of the treatment effect. Biometrics 1993; 49:1231-1236.
24. Leon AC, Hedeker D. Quintile Stratification Based on a Misspecified Propensity Score in Longitudinal Treatment Effectiveness Analyses of Ordinal Doses. Computational Statistics and Data Analysis 2007; 51:6114-6122.